Serum carbonic anhydrase I and II autoantibodies in patients with chronic lymphocytic leukaemia

Cancer is the second most important cause of mortality, and millions of people either have or have had the disease. Leukaemia is one of the most common forms of cancer. Autoantibodies that have developed against the organism's self-antigens are detected in the sera of subjects with cancer. In r...

Full description

Saved in:
Bibliographic Details
Published in:Central-European journal of immunology 2018-01, Vol.43 (3), p.276-280
Main Authors: Mentese, Ahmet, Erkut, Nergiz, Demir, Selim, Yaman, Serap Ozer, Sumer, Aysegul, Erdem, Mehmet, Alver, Ahmet, Sönmez, Mehmet Giray
Format: Article
Language:English
Subjects:
Antigens
Autoantibodies
autoantibody
Autoantigens
Autoimmune diseases
Cancer
carbonic anhydrase
Carbonic anhydrase I
Carcinoma
chronic lymphocytic leukaemia
Chronic lymphocytic leukemia
Clinical Immunology
Enzyme-linked immunosorbent assay
Immune response
Leukemia
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c487t-7880f4f0410fb0e8aeee700b025f5adf7ec5f36ae4c348ccad95a85d2af799d53
cites
container_end_page 280
container_issue 3
container_start_page 276
container_title Central-European journal of immunology
container_volume 43
creator Mentese, Ahmet
Erkut, Nergiz
Demir, Selim
Yaman, Serap Ozer
Sumer, Aysegul
Erdem, Mehmet
Alver, Ahmet
Sönmez, Mehmet Giray
description Cancer is the second most important cause of mortality, and millions of people either have or have had the disease. Leukaemia is one of the most common forms of cancer. Autoantibodies that have developed against the organism's self-antigens are detected in the sera of subjects with cancer. In recent years carbonic anhydrase (CA) autoantibodies have been determined in some autoimmune diseases and carcinomas, but the mechanisms underlying this immune response have not yet been fully explained. The purpose of this study was to determine CA I and II autoantibodies in subjects with chronic lymphocytic leukaemia (CLL) and to provide a novel perspective regarding the autoimmune basis of the disease. Autoantibody levels were investigated using enzyme-linked immunosorbent assay (ELISA) in serum samples from 37 patients with CLL and 37 healthy peers. Anti-CA I titres in the CLL group were significantly higher compared with the control group (p = 0.0001). However, there was no significant difference between CLL and control groups in terms of anti-CA II titres (p = 0.278). The prevalences of CA I and II autoantibodies in patients with CLL in this study were 27% and 24.3%, respectively. Our results suggest that these autoantibodies may be involved in the pathogenesis of CLL. More extensive studies are now needed to reveal the entire mechanism.
doi_str_mv 10.5114/ceji.2018.80046
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_dc91a92e11fe44aab2d2c138b86c9af5</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_dc91a92e11fe44aab2d2c138b86c9af5</doaj_id><sourcerecordid>2154636002</sourcerecordid><originalsourceid>FETCH-LOGICAL-c487t-7880f4f0410fb0e8aeee700b025f5adf7ec5f36ae4c348ccad95a85d2af799d53</originalsourceid><addsrcrecordid>eNpdks9u1DAQxiMEoqVw5oYiceGSre04jn1BQhV_IlXiAJzNxB53vSTxYiegfRuehSfD2S0V5TSj8W8-zYy_onhOyaahlF8a3PkNI1RuJCFcPCjOqeC84pTxhznnTFS1ouyseJLSjhChqFSPi7OaNFLSlp0XXz9hXMbSQOzD5E0J0_ZgIyQsu9-_YLJl15WwzAGm2ffBekyln8o9zB6nOZU__bwtzTYee4fDuN8Gc5jXHJdvgKOHp8UjB0PCZ7fxovjy7u3nqw_V9cf33dWb68pw2c5VKyVx3BFOiesJSkDElpCesMY1YF2LpnG1AOSm5tIYsKoB2VgGrlXKNvVF0Z10bYCd3kc_QjzoAF4fCyHeaIh5sgG1NYqCYkipQ84BemaZobXspTAK3Kr1-qS1X_oRrcmrRhjuid5_mfxW34QfWuTDCtpmgVe3AjF8XzDNevTJ4DDAhGFJmlFBiagVlxl9-R-6C0uc8qky1XBRC0JYpi5PlIkhpYjubhhK9OoEvTpBr07QRyfkjhf_7nDH__36-g-fmLKm</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2154636002</pqid></control><display><type>article</type><title>Serum carbonic anhydrase I and II autoantibodies in patients with chronic lymphocytic leukaemia</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><creator>Mentese, Ahmet ; Erkut, Nergiz ; Demir, Selim ; Yaman, Serap Ozer ; Sumer, Aysegul ; Erdem, Mehmet ; Alver, Ahmet ; Sönmez, Mehmet Giray</creator><creatorcontrib>Mentese, Ahmet ; Erkut, Nergiz ; Demir, Selim ; Yaman, Serap Ozer ; Sumer, Aysegul ; Erdem, Mehmet ; Alver, Ahmet ; Sönmez, Mehmet Giray</creatorcontrib><description>Cancer is the second most important cause of mortality, and millions of people either have or have had the disease. Leukaemia is one of the most common forms of cancer. Autoantibodies that have developed against the organism's self-antigens are detected in the sera of subjects with cancer. In recent years carbonic anhydrase (CA) autoantibodies have been determined in some autoimmune diseases and carcinomas, but the mechanisms underlying this immune response have not yet been fully explained. The purpose of this study was to determine CA I and II autoantibodies in subjects with chronic lymphocytic leukaemia (CLL) and to provide a novel perspective regarding the autoimmune basis of the disease. Autoantibody levels were investigated using enzyme-linked immunosorbent assay (ELISA) in serum samples from 37 patients with CLL and 37 healthy peers. Anti-CA I titres in the CLL group were significantly higher compared with the control group (p = 0.0001). However, there was no significant difference between CLL and control groups in terms of anti-CA II titres (p = 0.278). The prevalences of CA I and II autoantibodies in patients with CLL in this study were 27% and 24.3%, respectively. Our results suggest that these autoantibodies may be involved in the pathogenesis of CLL. More extensive studies are now needed to reveal the entire mechanism.</description><identifier>ISSN: 1426-3912</identifier><identifier>EISSN: 1644-4124</identifier><identifier>DOI: 10.5114/ceji.2018.80046</identifier><identifier>PMID: 30588172</identifier><language>eng</language><publisher>Poland: Termedia Publishing House</publisher><subject>Antigens ; Autoantibodies ; autoantibody ; Autoantigens ; Autoimmune diseases ; Cancer ; carbonic anhydrase ; Carbonic anhydrase I ; Carcinoma ; chronic lymphocytic leukaemia ; Chronic lymphocytic leukemia ; Clinical Immunology ; Enzyme-linked immunosorbent assay ; Immune response ; Leukemia</subject><ispartof>Central-European journal of immunology, 2018-01, Vol.43 (3), p.276-280</ispartof><rights>2018. This work is published under http://creativecommons.org/licenses/by-nc-sa/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright: © 2018 Polish Society of Experimental and Clinical Immunology 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c487t-7880f4f0410fb0e8aeee700b025f5adf7ec5f36ae4c348ccad95a85d2af799d53</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305617/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2154636002?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,44566,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30588172$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mentese, Ahmet</creatorcontrib><creatorcontrib>Erkut, Nergiz</creatorcontrib><creatorcontrib>Demir, Selim</creatorcontrib><creatorcontrib>Yaman, Serap Ozer</creatorcontrib><creatorcontrib>Sumer, Aysegul</creatorcontrib><creatorcontrib>Erdem, Mehmet</creatorcontrib><creatorcontrib>Alver, Ahmet</creatorcontrib><creatorcontrib>Sönmez, Mehmet Giray</creatorcontrib><title>Serum carbonic anhydrase I and II autoantibodies in patients with chronic lymphocytic leukaemia</title><title>Central-European journal of immunology</title><addtitle>Cent Eur J Immunol</addtitle><description>Cancer is the second most important cause of mortality, and millions of people either have or have had the disease. Leukaemia is one of the most common forms of cancer. Autoantibodies that have developed against the organism's self-antigens are detected in the sera of subjects with cancer. In recent years carbonic anhydrase (CA) autoantibodies have been determined in some autoimmune diseases and carcinomas, but the mechanisms underlying this immune response have not yet been fully explained. The purpose of this study was to determine CA I and II autoantibodies in subjects with chronic lymphocytic leukaemia (CLL) and to provide a novel perspective regarding the autoimmune basis of the disease. Autoantibody levels were investigated using enzyme-linked immunosorbent assay (ELISA) in serum samples from 37 patients with CLL and 37 healthy peers. Anti-CA I titres in the CLL group were significantly higher compared with the control group (p = 0.0001). However, there was no significant difference between CLL and control groups in terms of anti-CA II titres (p = 0.278). The prevalences of CA I and II autoantibodies in patients with CLL in this study were 27% and 24.3%, respectively. Our results suggest that these autoantibodies may be involved in the pathogenesis of CLL. More extensive studies are now needed to reveal the entire mechanism.</description><subject>Antigens</subject><subject>Autoantibodies</subject><subject>autoantibody</subject><subject>Autoantigens</subject><subject>Autoimmune diseases</subject><subject>Cancer</subject><subject>carbonic anhydrase</subject><subject>Carbonic anhydrase I</subject><subject>Carcinoma</subject><subject>chronic lymphocytic leukaemia</subject><subject>Chronic lymphocytic leukemia</subject><subject>Clinical Immunology</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Immune response</subject><subject>Leukemia</subject><issn>1426-3912</issn><issn>1644-4124</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdks9u1DAQxiMEoqVw5oYiceGSre04jn1BQhV_IlXiAJzNxB53vSTxYiegfRuehSfD2S0V5TSj8W8-zYy_onhOyaahlF8a3PkNI1RuJCFcPCjOqeC84pTxhznnTFS1ouyseJLSjhChqFSPi7OaNFLSlp0XXz9hXMbSQOzD5E0J0_ZgIyQsu9-_YLJl15WwzAGm2ffBekyln8o9zB6nOZU__bwtzTYee4fDuN8Gc5jXHJdvgKOHp8UjB0PCZ7fxovjy7u3nqw_V9cf33dWb68pw2c5VKyVx3BFOiesJSkDElpCesMY1YF2LpnG1AOSm5tIYsKoB2VgGrlXKNvVF0Z10bYCd3kc_QjzoAF4fCyHeaIh5sgG1NYqCYkipQ84BemaZobXspTAK3Kr1-qS1X_oRrcmrRhjuid5_mfxW34QfWuTDCtpmgVe3AjF8XzDNevTJ4DDAhGFJmlFBiagVlxl9-R-6C0uc8qky1XBRC0JYpi5PlIkhpYjubhhK9OoEvTpBr07QRyfkjhf_7nDH__36-g-fmLKm</recordid><startdate>20180101</startdate><enddate>20180101</enddate><creator>Mentese, Ahmet</creator><creator>Erkut, Nergiz</creator><creator>Demir, Selim</creator><creator>Yaman, Serap Ozer</creator><creator>Sumer, Aysegul</creator><creator>Erdem, Mehmet</creator><creator>Alver, Ahmet</creator><creator>Sönmez, Mehmet Giray</creator><general>Termedia Publishing House</general><general>Polish Society of Experimental and Clinical Immunology</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20180101</creationdate><title>Serum carbonic anhydrase I and II autoantibodies in patients with chronic lymphocytic leukaemia</title><author>Mentese, Ahmet ; Erkut, Nergiz ; Demir, Selim ; Yaman, Serap Ozer ; Sumer, Aysegul ; Erdem, Mehmet ; Alver, Ahmet ; Sönmez, Mehmet Giray</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c487t-7880f4f0410fb0e8aeee700b025f5adf7ec5f36ae4c348ccad95a85d2af799d53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Antigens</topic><topic>Autoantibodies</topic><topic>autoantibody</topic><topic>Autoantigens</topic><topic>Autoimmune diseases</topic><topic>Cancer</topic><topic>carbonic anhydrase</topic><topic>Carbonic anhydrase I</topic><topic>Carcinoma</topic><topic>chronic lymphocytic leukaemia</topic><topic>Chronic lymphocytic leukemia</topic><topic>Clinical Immunology</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Immune response</topic><topic>Leukemia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mentese, Ahmet</creatorcontrib><creatorcontrib>Erkut, Nergiz</creatorcontrib><creatorcontrib>Demir, Selim</creatorcontrib><creatorcontrib>Yaman, Serap Ozer</creatorcontrib><creatorcontrib>Sumer, Aysegul</creatorcontrib><creatorcontrib>Erdem, Mehmet</creatorcontrib><creatorcontrib>Alver, Ahmet</creatorcontrib><creatorcontrib>Sönmez, Mehmet Giray</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Biological Sciences</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Open Access: DOAJ - Directory of Open Access Journals</collection><jtitle>Central-European journal of immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mentese, Ahmet</au><au>Erkut, Nergiz</au><au>Demir, Selim</au><au>Yaman, Serap Ozer</au><au>Sumer, Aysegul</au><au>Erdem, Mehmet</au><au>Alver, Ahmet</au><au>Sönmez, Mehmet Giray</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum carbonic anhydrase I and II autoantibodies in patients with chronic lymphocytic leukaemia</atitle><jtitle>Central-European journal of immunology</jtitle><addtitle>Cent Eur J Immunol</addtitle><date>2018-01-01</date><risdate>2018</risdate><volume>43</volume><issue>3</issue><spage>276</spage><epage>280</epage><pages>276-280</pages><issn>1426-3912</issn><eissn>1644-4124</eissn><abstract>Cancer is the second most important cause of mortality, and millions of people either have or have had the disease. Leukaemia is one of the most common forms of cancer. Autoantibodies that have developed against the organism's self-antigens are detected in the sera of subjects with cancer. In recent years carbonic anhydrase (CA) autoantibodies have been determined in some autoimmune diseases and carcinomas, but the mechanisms underlying this immune response have not yet been fully explained. The purpose of this study was to determine CA I and II autoantibodies in subjects with chronic lymphocytic leukaemia (CLL) and to provide a novel perspective regarding the autoimmune basis of the disease. Autoantibody levels were investigated using enzyme-linked immunosorbent assay (ELISA) in serum samples from 37 patients with CLL and 37 healthy peers. Anti-CA I titres in the CLL group were significantly higher compared with the control group (p = 0.0001). However, there was no significant difference between CLL and control groups in terms of anti-CA II titres (p = 0.278). The prevalences of CA I and II autoantibodies in patients with CLL in this study were 27% and 24.3%, respectively. Our results suggest that these autoantibodies may be involved in the pathogenesis of CLL. More extensive studies are now needed to reveal the entire mechanism.</abstract><cop>Poland</cop><pub>Termedia Publishing House</pub><pmid>30588172</pmid><doi>10.5114/ceji.2018.80046</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1426-3912
ispartof Central-European journal of immunology, 2018-01, Vol.43 (3), p.276-280
issn 1426-3912
1644-4124
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_dc91a92e11fe44aab2d2c138b86c9af5
source Open Access: PubMed Central; Publicly Available Content Database
subjects Antigens
Autoantibodies
autoantibody
Autoantigens
Autoimmune diseases
Cancer
carbonic anhydrase
Carbonic anhydrase I
Carcinoma
chronic lymphocytic leukaemia
Chronic lymphocytic leukemia
Clinical Immunology
Enzyme-linked immunosorbent assay
Immune response
Leukemia
title Serum carbonic anhydrase I and II autoantibodies in patients with chronic lymphocytic leukaemia
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T14%3A24%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20carbonic%20anhydrase%20I%C2%A0and%20II%20autoantibodies%20in%20patients%20with%20chronic%20lymphocytic%20leukaemia&rft.jtitle=Central-European%20journal%20of%20immunology&rft.au=Mentese,%20Ahmet&rft.date=2018-01-01&rft.volume=43&rft.issue=3&rft.spage=276&rft.epage=280&rft.pages=276-280&rft.issn=1426-3912&rft.eissn=1644-4124&rft_id=info:doi/10.5114/ceji.2018.80046&rft_dat=%3Cproquest_doaj_%3E2154636002%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c487t-7880f4f0410fb0e8aeee700b025f5adf7ec5f36ae4c348ccad95a85d2af799d53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2154636002&rft_id=info:pmid/30588172&rfr_iscdi=true